xanthohumol and Hypercholesterolemia

xanthohumol has been researched along with Hypercholesterolemia* in 2 studies

Other Studies

2 other study(ies) available for xanthohumol and Hypercholesterolemia

ArticleYear
Xanthohumol, a hop-derived prenylated flavonoid, promotes macrophage reverse cholesterol transport.
    The Journal of nutritional biochemistry, 2017, Volume: 47

    Xanthohumol, a prominent prenyl flavonoid from the hop plant (Humulus lupulus L.), is suggested to be antiatherogenic since it reportedly increases high-density lipoprotein (HDL) cholesterol levels. It is not clear whether xanthohumol promotes reverse cholesterol transport (RCT), the most important antiatherogenic property of HDL; therefore, we investigated the effects of xanthohumol on macrophage-to-feces RCT using a hamster model as a CETP-expressing species. In vivo RCT experiments showed that xanthohumol significantly increased fecal appearance of the tracer derived from intraperitoneally injected [

    Topics: Animals; Anticholesteremic Agents; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 8; Biological Transport; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cholesterol Ester Transfer Proteins; Diet, High-Fat; Dietary Supplements; Feces; Flavonoids; Gastrointestinal Agents; Gene Expression Regulation, Developmental; Hypercholesterolemia; Intestinal Elimination; Lipoproteins, HDL; Liver; Macrophages; Male; Mesocricetus; Phosphatidylcholine-Sterol O-Acyltransferase; Propiophenones

2017
Xanthohumol ameliorates atherosclerotic plaque formation, hypercholesterolemia, and hepatic steatosis in ApoE-deficient mice.
    Molecular nutrition & food research, 2013, Volume: 57, Issue:10

    Xanthohumol (XN), a prenylated antioxidative and anti-inflammatory chalcone from hops, exhibits positive effects on lipid and glucose metabolism. Based on its favorable biological properties, we investigated whether XN attenuates atherosclerosis in western-type diet-fed apolipoprotein-E-deficient (ApoE⁻/⁻) mice.. XN supplementation markedly reduced plasma cholesterol concentrations, decreased atherosclerotic lesion area, and attenuated plasma concentrations of the proinflammatory cytokine monocyte chemoattractant protein 1. Decreased hepatic triglyceride and cholesterol content, activation of AMP-activated protein kinase, phosphorylation and inactivation of acetyl-CoA carboxylase, and reduced expression levels of mature sterol regulatory element-binding protein (SREBP)-2 and SREBP-1c mRNA indicate reduced lipogenesis in the liver of XN-fed ApoE⁻/⁻ mice. Concomitant induction of hepatic mRNA expression of carnitine palmitoyltransferase-1a in ApoE⁻/⁻ mice-administered XN suggests increased fatty acid beta-oxidation. Fecal cholesterol concentrations were also markedly increased in XN-fed ApoE⁻/⁻ mice compared with mice fed western-type diet alone.. The atheroprotective effects of XN might be attributed to combined beneficial effects on plasma cholesterol and monocyte chemoattractant protein 1 concentrations and hepatic lipid metabolism via activation of AMP-activated protein kinase.

    Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Carnitine O-Palmitoyltransferase; Chemokine CCL2; Cholesterol; Fatty Liver; Female; Flavonoids; Hypercholesterolemia; Lipid Metabolism; Lipogenesis; Liver; Mice; Phosphorylation; Plaque, Atherosclerotic; Propiophenones; RNA, Messenger; Sterol Regulatory Element Binding Protein 1; Sterol Regulatory Element Binding Protein 2; Triglycerides

2013
chemdatabank.com